Drugs Made In America Acq... (DMII)
NasdaqGM: DMII
· Real-Time Price · USD
10.13
+0.00 (0.00%)
At close: Aug 12, 2026, 1:20 PM
Drugs Made In America Acquisition II Corp. (DMII) Stock Price, Analysis & Data
0.00% (1D)
| Bid | 10.11 |
| Market Cap | 645.28M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 8.58M |
| Beta | n/a |
| EPS (ttm) | 0.13 |
| PE Ratio (ttm) | 77.92 |
| Forward PE | n/a |
| P/B (ttm) | -36.18 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 10.09 |
| Volume | 30 |
| Avg. Volume (20D) | 61,669 |
| Open | 10.13 |
| Previous Close | 10.13 |
| Day's Range | 10.13 - 10.13 |
| 52-Week Range | 9.86 - 10.20 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DMII
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York...
Industry Shell Companies
Sector Financial Services
IPO Date Dec 3, 2025
Employees n/a
Stock Exchange NasdaqGM
Ticker Symbol DMII
Financial Performance
In 2025, Drugs Made In America Acquisition II's revenue was 0, an increase of undefined% compared to the previous year's n/a. Earnings were 4.19M, an increase of undefined%.
Financial Statements
